McKimm-Breschkin J - Search Results

1

Complexity in influenza virus targeted drug design: interaction with human sialidases.

Chavas LM, Kato R, Suzuki N, von Itzstein M, Mann MC, Thomson RJ, Dyason JC, McKimm-Breschkin J, Fusi P, Tringali C, Venerando B, Tettamanti G, Monti E, Wakatsuki S. Chavas LM, et al. J Med Chem. 2010 Apr 8;53(7):2998-3002. doi: 10.1021/jm100078r. J Med Chem. 2010. PMID: 20222714

2

Structural and functional basis of resistance to neuraminidase inhibitors of influenza B viruses.

Oakley AJ, Barrett S, Peat TS, Newman J, Streltsov VA, Waddington L, Saito T, Tashiro M, McKimm-Breschkin JL. Oakley AJ, et al. J Med Chem. 2010 Sep 9;53(17):6421-31. doi: 10.1021/jm100621s. J Med Chem. 2010. PMID: 20695427 Free PMC article.

3

Dimeric zanamivir conjugates with various linking groups are potent, long-lasting inhibitors of influenza neuraminidase including H5N1 avian influenza.

Macdonald SJ, Cameron R, Demaine DA, Fenton RJ, Foster G, Gower D, Hamblin JN, Hamilton S, Hart GJ, Hill AP, Inglis GG, Jin B, Jones HT, McConnell DB, McKimm-Breschkin J, Mills G, Nguyen V, Owens IJ, Parry N, Shanahan SE, Smith D, Watson KG, Wu WY, Tucker SP. Macdonald SJ, et al. J Med Chem. 2005 Apr 21;48(8):2964-71. doi: 10.1021/jm040891b. J Med Chem. 2005. PMID: 15828835

4

Structural and Functional Analysis of Anti-Influenza Activity of 4-, 7-, 8- and 9-Deoxygenated 2,3-Difluoro- N-acetylneuraminic Acid Derivatives.

McKimm-Breschkin JL, Barrett S, Pilling PA, Hader S, Watts AG, Streltsov VA. McKimm-Breschkin JL, et al. J Med Chem. 2018 Mar 8;61(5):1921-1933. doi: 10.1021/acs.jmedchem.7b01467. Epub 2018 Feb 15. J Med Chem. 2018. PMID: 29397718

5

Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996-2007.

Tashiro M, McKimm-Breschkin JL, Saito T, Klimov A, Macken C, Zambon M, Hayden FG; Neuraminidase Inhibitor Susceptibility Network. Tashiro M, et al. Antivir Ther. 2009;14(6):751-61. doi: 10.3851/IMP1194. Antivir Ther. 2009. PMID: 19812437

6

Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance.

McKimm-Breschkin JL. McKimm-Breschkin JL. Influenza Other Respir Viruses. 2013 Jan;7 Suppl 1(Suppl 1):25-36. doi: 10.1111/irv.12047. Influenza Other Respir Viruses. 2013. PMID: 23279894 Free PMC article. Review.

7

Mutations conferring zanamivir resistance in human influenza virus N2 neuraminidases compromise virus fitness and are not stably maintained in vitro.

Zürcher T, Yates PJ, Daly J, Sahasrabudhe A, Walters M, Dash L, Tisdale M, McKimm-Breschkin JL. Zürcher T, et al. J Antimicrob Chemother. 2006 Oct;58(4):723-32. doi: 10.1093/jac/dkl321. Epub 2006 Aug 5. J Antimicrob Chemother. 2006. PMID: 16891631

8

Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network.

Wetherall NT, Trivedi T, Zeller J, Hodges-Savola C, McKimm-Breschkin JL, Zambon M, Hayden FG. Wetherall NT, et al. J Clin Microbiol. 2003 Feb;41(2):742-50. doi: 10.1128/JCM.41.2.742-750.2003. J Clin Microbiol. 2003. PMID: 12574276 Free PMC article.

9

Management of influenza virus infections with neuraminidase inhibitors: detection, incidence, and implications of drug resistance.

McKimm-Breschkin JL. McKimm-Breschkin JL. Treat Respir Med. 2005;4(2):107-16. doi: 10.2165/00151829-200504020-00004. Treat Respir Med. 2005. PMID: 15813662 Free PMC article. Review.

10

Reduced sensitivity of influenza A (H5N1) to oseltamivir.

McKimm-Breschkin JL, Selleck PW, Usman TB, Johnson MA. McKimm-Breschkin JL, et al. Emerg Infect Dis. 2007 Sep;13(9):1354-7. doi: 10.3201/eid1309.070164. Emerg Infect Dis. 2007. PMID: 18252107 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

90 results

Search Page